This study is a 52-week, randomized, open, active-controlled trial of patients with active
diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic
agent iguratimod. The subjects will randomly receive iguratimod or cyclophosphamide followed
with azathioprine, both combined with steroids.